China SXT Pharmaceuticals (SXTC) Construction in Progress (2018 - 2023)

China SXT Pharmaceuticals (SXTC) has reported Construction in Progress for 6 consecutive years, with $349390.0 the latest figure, recorded in Q1 2023.

• Quarterly Construction in Progress fell 3.77% year-over-year to $349390.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $349390.0 (down 3.77% YoY) and the FY2023 annual result came in at $349390.0, down 3.77% from the prior year.
• Construction in Progress improved to $349390.0 in Q1 2023 per SXTC's latest filing, from $343153.0 in the prior quarter.
• Over the last five years, Construction in Progress for SXTC reached as high as $649235.0 in Q1 2019 and fell as low as $180000.0 in Q3 2019.
• A 5-year average of $375208.3 and a median of $355614.0 in 2021 frame the typical range for Construction in Progress.
• Annual changes were most pronounced in 2019 — Construction in Progress plunged 68.58% — and 2020, when it jumped 149.7%.
• Year by year, Construction in Progress stood at $180000.0 in 2019, then soared by 149.7% to $449464.0 in 2020, then declined by 20.22% to $358569.0 in 2021, then dropped by 4.3% to $343153.0 in 2022, then climbed by 1.82% to $349390.0 in 2023.
• According to Business Quant data, Construction in Progress over the past three periods registered $349390.0, $343153.0, and $363078.0 for Q1 2023, Q3 2022, and Q1 2022 respectively.